NDC 0023-6501
UBRELVY
Ubrogepant
UBRELVY is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Allergan, Inc.. The primary component is Ubrogepant.
| Product ID | 0023-6501_179b083b-faaf-4092-9f87-005dab651067 |
| NDC | 0023-6501 |
| Product Type | Human Prescription Drug |
| Proprietary Name | UBRELVY |
| Generic Name | Ubrogepant |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2019-12-23 |
| Marketing Category | NDA / NDA |
| Application Number | NDA211765 |
| Labeler Name | Allergan, Inc. |
| Substance Name | UBROGEPANT |
| Active Ingredient Strength | 100 mg/1 |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
Packaging
NDC 0023-6501-10
10 PACKET in 1 BOX (0023-6501-10) > 1 TABLET in 1 PACKET (0023-6501-02)
| Marketing Start Date | 2019-12-23 |
| NDC Exclude Flag | N |
| Sample Package? | N |
NDC SPL Data Element Entries
NDC 0023-6501-02 [00023650102]
UBRELVY TABLET
| Marketing Category | NDA |
| Application Number | NDA211765 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2019-12-23 |
NDC 0023-6501-30 [00023650130]
UBRELVY TABLET
| Marketing Category | NDA |
| Application Number | NDA211765 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2019-12-23 |
NDC 0023-6501-08 [00023650108]
UBRELVY TABLET
| Marketing Category | NDA |
| Application Number | NDA211765 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2019-12-23 |
NDC 0023-6501-10 [00023650110]
UBRELVY TABLET
| Marketing Category | NDA |
| Application Number | NDA211765 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2019-12-23 |
NDC 0023-6501-12 [00023650112]
UBRELVY TABLET
| Marketing Category | NDA |
| Application Number | NDA211765 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2019-12-23 |
NDC 0023-6501-06 [00023650106]
UBRELVY TABLET
| Marketing Category | NDA |
| Application Number | NDA211765 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2019-12-23 |
Drug Details
Active Ingredients
| Ingredient | Strength |
|---|---|
| UBROGEPANT | 100 mg/1 |
NDC Crossover Matching brand name "UBRELVY" or generic name "Ubrogepant"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0023-6498 | UBRELVY | ubrogepant |
| 0023-6501 | UBRELVY | ubrogepant |
Trademark Results [UBRELVY]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 UBRELVY 88185227 not registered Live/Pending |
Allergan Pharmaceuticals International Limited 2018-11-07 |
 UBRELVY 88155130 not registered Live/Pending |
ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED 2018-10-15 |
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.